Bayer bought the American biotechnology company Asklepios BioPharmaceutical for € 3,3 billion, thus targeting batteries for gene therapies with the help of modified viruses, reports the agency "Reuters" this Monday, October 26.
The German company will pay half of the money, while the other half will be paid according to the objectives achieved by the North American company, based in North Carolina.
Among the projects in the greatest development phase of AskBio are the first voluntary tests on a potential treatment against Pompe's disease, a rare genetic disease that causes the accumulation of a sugar molecule inside the cells.
The biotechnology company has also developed projects to combat Parkinson's disease or heart failure problems. A potential treatment against Duchenne muscular dystrophy, created by AskBio, is currently being developed in clinical trials by Pfizer.